On-demand PPI requirements in patients with endoscopy-negative GERD

Journal of Clinical Gastroenterology

Volumn 38, Issue 9, 2004, Pages 746-749

  Juul Hansen, Paul ^a,b   Rydning, Andreas ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b Rasta Medical Centre   (Norway)

Author keywords

Endoscopy negative; Esophageal pH monitoring; Gastroesophageal reflux; Lansoprazole; On demand

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL ARTICLE; DRUG CAPSULE; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; LOWER ESOPHAGUS SPHINCTER; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; CAPSULES; DRUG ADMINISTRATION SCHEDULE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; TREATMENT OUTCOME;

EID: 4644250904     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000139033.30945.7f     Document Type: Article

References (19)

1. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut. 1999;44:1-16.
2. Lind T, Havelund T, Carlsson R, et al. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974-979.
3. Fass R, Fennerty MB, Vakil N. Nonerosive Reflux Disease - current concepts and dilemmas. Am J Gastroenterol. 2001;96.
4. Jones RH, Hungin APS, Phillips J, et al. J. Gastro-esophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract. 1995;1:149-154.
5. Johnsson F, Weywadt L, Solhaug JH, et al. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux Disease. Scand J Gastroenterol. 1998;33:15-20.
6. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999;159:2161-2168.
7. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997;92:1997-2000.
8. Juul-Hansen P, Rydning A, Jacobsen CD, et al. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol. 2001;136:806-810.
9. Smout AJPM. Endoscopy-negative reflux disease. Aliment Pharmacol Ther. 1997;11(Suppl 2):81-86.
10. Tew S, Jamieson GG, Pilowsky I, et al. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus. 1997;10:9-15.
11. Johnsson F, Moum B, Vilien M, et al. On-demand treatment in patients with esophagitis and refluxsymptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol. 2002;37:642-647.
12. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without esophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther (England). 1999;13:p907-p914.
13. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-esophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months [In Process Citation] Eur J Gastroenterol Hepatol (England). 2002;14:p857-p863.
14. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of "on-demand" therapy for 6 months. Aliment Pharmacol Ther. 2001;15:347-354.
15. Vakil N. Cost-effectiveness of different GERD management strategies. Aliment Pharmacol Ther. 2002;16(Suppl 4):79-82.
16. Waldum HL, Arnestad JS, Brenna E, et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 1996;39:649-653.
17. Gillen D, Wirz AA, Ardill JE, et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. [comment] Gastroenterology. 1999;116:239-247.
18. Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol. 2001;33:206-209.
19. Bell N, Karol MD, Sachs G, et al. Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment Pharmacol Ther. 2001;15:105-113.